Explore All Access
Check if your research matches the topics covered in PSORIASIS-TARGETS AND THERAPY?
- Degree of match
- Common matching concepts
- Additional journal recommendations
PSORIASIS-TARGETS AND THERAPY : Impact Factor & More
eISSN: 2230-326XpISSN: 2230-326X
Open AccessShare this on:
Check your submission readiness
Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.
PSORIASIS-TARGETS AND THERAPY Key Metrics
Time to Accept 
3
Mo
Time to Publish
View Chart Mo
Time to Publish
Sign up now and unlock a detailed chart of Time to publish for this journal
% of papers by time taken from submission to publication
0 to 3 months33%
4 to 6 months50%
7 to 9 months8%
Above 9 months8%
Did you find this useful?
PSORIASIS-TARGETS AND THERAPY Journal Specifications
Indexed in the following public directories
Web of Science 
DOAJ
| Overview | |
| Publisher | DOVE MEDICAL PRESS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2390 |
| Publication Time | 16 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2011 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in PSORIASIS-TARGETS AND THERAPY ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in PSORIASIS-TARGETS AND THERAPY
Unveiling Novel Protein Biomarkers for Psoriasis Through Integrated Analysis of Human Plasma Proteomics and Mendelian Randomization.
- 1 Dec 2024
- Psoriasis (Auckland, N.Z.)
Zinc Supplementation for Acrodermatitis Enteropathica Overlapped with Psoriasiform Lesions.
- 1 Nov 2024
- Psoriasis (Auckland, N.Z.)
Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review.
- 1 Nov 2024
- Psoriasis (Auckland, N.Z.)
Impact of IL-17A Inhibitors on Serum Uric Acid Levels in Psoriatic Patients with Hyperuricemia: A Prospective Observational Study.
- 1 Nov 2024
- Psoriasis (Auckland, N.Z.)
Psoriasis Flare Following Paramyxovirus Infection.
- 1 Nov 2024
- Psoriasis (Auckland, N.Z.)
The Association Between Patient-Reported Disease Burden and Treatment Switching in Patients with Plaque Psoriasis Treated with Nonbiologic Systemic Therapy.
- 1 Nov 2024
- Psoriasis (Auckland, N.Z.)
Unveiling Novel Protein Biomarkers for Psoriasis Through Integrated Analysis of Human Plasma Proteomics and Mendelian Randomization.
- 1 Dec 2024
- Psoriasis (Auckland, N.Z.)
Zinc Supplementation for Acrodermatitis Enteropathica Overlapped with Psoriasiform Lesions.
- 1 Nov 2024
- Psoriasis (Auckland, N.Z.)
Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review.
- 1 Nov 2024
- Psoriasis (Auckland, N.Z.)
Impact of IL-17A Inhibitors on Serum Uric Acid Levels in Psoriatic Patients with Hyperuricemia: A Prospective Observational Study.
- 1 Nov 2024
- Psoriasis (Auckland, N.Z.)
Psoriasis Flare Following Paramyxovirus Infection.
- 1 Nov 2024
- Psoriasis (Auckland, N.Z.)
The Association Between Patient-Reported Disease Burden and Treatment Switching in Patients with Plaque Psoriasis Treated with Nonbiologic Systemic Therapy.
- 1 Nov 2024
- Psoriasis (Auckland, N.Z.)
FAQs on PSORIASIS-TARGETS AND THERAPY
How long has PSORIASIS-TARGETS AND THERAPY been actively publishing? 
PSORIASIS-TARGETS AND THERAPY has been in operation since 2011 till date.
What is the publishing frequency of PSORIASIS-TARGETS AND THERAPY?
PSORIASIS-TARGETS AND THERAPY published with a Continuous publication frequency.
How many articles did PSORIASIS-TARGETS AND THERAPY publish last year?
In 2023, PSORIASIS-TARGETS AND THERAPY publsihed 7 articles.
What is the eISSN & pISSN for PSORIASIS-TARGETS AND THERAPY?
For PSORIASIS-TARGETS AND THERAPY, eISSN is 2230-326X and pISSN is 2230-326X.
Who is the publisher of PSORIASIS-TARGETS AND THERAPY?
DOVE MEDICAL PRESS LTD is the publisher of PSORIASIS-TARGETS AND THERAPY.
